How long does it usually take to see the effects of Seladelpar?

Seladelpar (Seladelpar) is a new type of drug used to treat primary biliary cholangitis (PBC) is an oral drug whose main target is the PPARδ receptor. It improves intrahepatic bile excretion and reduces the inflammatory response caused by cholestasis, thereby alleviating symptoms such as itching and fatigue, and improving related biochemical indicators. For most patients, the therapeutic effect is usually not immediately apparent, but gradually manifested after continuous and regular use, so understanding its onset of action is particularly important for long-term management of chronic cholestatic diseases.

The improvement of biochemical indicators of Siladepa may gradually appear over weeks to months after continuous use, especially the decline rate of cholestasis-related indicators such as alkaline phosphatase is relatively stable. Some patients can observe a reduction in symptoms such as fatigue and itching after a few weeks of treatment, but more comprehensive and stable improvements in hepatobiliary indicators often require longer periods of continuous medication. Considering that primary biliary cholangitis is a chronic immune-related disease with long-term disease progression, Siladepa, as a maintenance treatment drug, emphasizes persistence, stability and long-term benefits rather than rapid onset of effect.

In addition, the onset of effect may be affected by factors such as the stage of the disease, whether UDCA is used at the same time, patients' metabolic differences, and whether they are combined with autoimmune diseases. For example, patients who have a poor response to UDCA but continue to take UDCA combination therapy may observe improvements in biochemical parameters earlier under the combination regimen. For patients who cannot tolerate UDCA and take Siladepa alone, the efficacy evaluation requires doctors to make comprehensive judgments on symptom changes, biochemical index trends, and liver imaging manifestations.

Reference materials:https://go.drugbank.com/drugs/DB12390